In a world where resistance to antibiotics is a growing concern, the need for more innovative and effective solutions for wound care and infectious skin disease treatments has never been more urgent.
HAIs (healthcare-acquired infections) pose a serious threat to the health and safety of millions of patients in the US alone each year. According to the CDC (Centers for Disease Control and Prevention), just in US hospitals alone, at any given time, there are about 1 in 31 hospitalized patients that have at least 1 HAI, with more than 680,000 infections and billions of dollars in excess health care costs related to HAIs across the United States every year. Furthermore, many of these hospital-acquired infections are caused by antibiotic-resistant (AR) pathogens. HAIs and other infections can also lead to sepsis, which causes approximately 1.7 million illnesses and 270,000 deaths annually in the US too.
Reducing HAIs across all health care settings is a prime motivator for ViaDerma, especially if more widespread use of their lead Vitastem Ultra is used as a wound care treatment and to prevent infections like staph & MRSA, which are two of the main culprits of HAIs.
Who is ViaDerma? They’re a groundbreaking pharmaceutical company that is rising to the challenge by developing and licensing the world’s most potent broad-spectrum topical antibiotics for these conditions. Their revolutionary dual carrier transdermal delivery technology can transform oral medications into topical ointments, providing rapid and targeted results.
In this article, we’ll explore the journey of ViaDerma, its lead product Vitastem Ultra, and the potential impact of its cutting-edge technology on the global healthcare industry.
We also share several insights from Dr. Christopher Otiko, the founder of ViaDerma, as he discusses the company’s mission, the effectiveness of Vitastem Ultra against antibiotic-resistant bacteria, such as staph infection, MRSA (flesh-eating bacteria), and the vast markets they aim to serve globally.
Our Interview with ViaDerma’s CEO, Dr. Otiko
What made you decide to create your company ViaDerma?
I wanted to start up a company that could produce medication and help save a lot of lives.
What types of infectious skin diseases & wounds does your tech help heal?
ViaDerma’s lead product Vitastem Ultra is an FDA-registered drug and one of the world’s strongest topical antibiotics available. To date, it has been highly successful at killing all harmful Gram-positive and Gram-negative bacteria that have been available for testing, such as eczema, psoriasis, acne, burns, cuts & scrapes, etc. In addition to these conditions, Vitastem can kill antibiotic-resistant bacteria like staph infection & MRSA too.
ViaDerma’s Vitastem Ultra can kill antibiotic-resistant bacteria like MRSA?
Yes, and far more effectively than other products available on the market. It’s partly due to Vitastem Ultra being the only antibiotic in the world that kills with both a physical and chemical mechanism – this gives it a unique ability to overcome drug resistant bacteria like MRSA which can causes severe health complications and death.
Who do you develop & license your transdermal technology solutions for?
Our solutions are available for licensing to leaders in the pharmaceutical, wound care, pet care, and cosmetics industries. From hospitals, surgery centers, nursing homes, wound care facilities, and dermatologists, to veterinarians, sports injuries, and more.
How big are the markets you are targeting worldwide?
From recent research studies, we can provide solutions to global markets that exceed over $360 billion in revenue yearly and growing quickly.
Moving Forward with ViaDerma
ViaDerma has demonstrated an unwavering commitment to revolutionizing treatments for wound care and variety of infectious skin diseases through the development and licensing of their unique and extremely valuable transdermal delivery system.
Their lead product, Vitastem Ultra, is not only effective against treating & healing common skin conditions, but also holds the potential to combat antibiotic-resistant bacteria like MRSA. This groundbreaking approach can help address the growing concern of antibiotic resistance and save countless lives.
As the company continues to expand its reach, it remains dedicated to collaborating with leaders in the pharmaceutical, wound care, pet care, and cosmetics industries. By providing innovative solutions to global markets generating over $366 billion in annual revenue and growing, ViaDerma has positioned itself as a significant player in the healthcare landscape.
In a world where the demand for advanced, effective, and versatile treatment options is ever-increasing, ViaDerma and its remarkable transdermal technology have the potential to profoundly impact patient care and outcomes.
As Dr. Christopher Otiko and his team continue their mission to improve lives, they not only offer hope to those suffering from infectious skin diseases and wounds but also pave the way for a future where antibiotic resistance can be more effectively managed and overcome with the use of advanced topical antibiotics like Vitastem.